S'abonner

Improvements in Lung Function and Height among Cohorts of 6-Year-Olds with Cystic Fibrosis from 1994 to 2012 - 21/11/14

Doi : 10.1016/j.jpeds.2014.06.061 
Donald R. VanDevanter, PhD 1, , David J. Pasta, MS 2, Michael W. Konstan, MD 1, 3
1 Pediatrics, Case Western Reserve University School of Medicine, Cleveland, OH 
2 Medical Affairs and Statistical Analysis, ICON Clinical Research, San Francisco, CA 
3 Pediatrics, Rainbow Babies and Children's Hospital, Cleveland, OH 

Reprint requests: Donald R. VanDevanter, PhD, 12520 33rd Street, Ct E, Edgewood, WA 98372.

Abstract

Objective

To characterize spirometry and height changes in cohorts of 6-year-old children with cystic fibrosis (CF).

Study design

Global Lung Initiative forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), and FEV1/FVC, and the Centers for Disease Control and Prevention height-for-age (HFA) z-scores were generated for 6-year-old children from the Cystic Fibrosis Foundation Patient Registry each year between 1994 and 2012. Z-score mean differences were analyzed by the t test, and time trends of means were analyzed by least squares regression for all children and for subgroups of sex, F508del mutation genotype, Medicaid insurance, and prenatal/newborn screening identification. Z-score distributions were compared using the 2-sample Kolmogorov-Smirnov test.

Results

A total of 11 670 children with CF were studied, of whom 50.5% were males, 50.2% had the F508del/F508del genotype, and 46.6% were insured by Medicaid. Mean HFA, FEV1, and FVC z-scores increased significantly over the period in the entire cohort and in all subgroups (P < .001), but FEV1/FVC z-scores were below normal and did not change significantly. In 2012, children identified by screening had significantly higher mean HFA (P = .002), FEV1 (P < .001), and FVC (P < .001) z-scores compared with children not screened, with 90% of FVC and 71.4% of FEV1 z-scores greater than predicted by the normal distribution. FEV1/FVC z-scores were not different between the children who were and were not screened.

Conclusion

Consistent, significant increases in HFA, FEV1, and FVC occurred between 1994 and 2012, but FEV1/FVC, a measure of airway obstruction, did not change appreciably during this period. FVC and FEV1 z-score distributions suggest that normative equation reference populations underpredict lung volumes of children with CF, but the reasons for this remain unclear.

Le texte complet de cet article est disponible en PDF.

Keyword : CF, CFFPR, FEF25-75, FEV1, FEV1% predicted, FVC, GLI, HFA


Plan


 M.K. was supported by the National Institutes of Health (P30 DK27651) and the Cystic Fibrosis Foundation (CFFT KONSTA09Y0), and has served as an advisor/investigator for Aradigm, Celtaxsys, Digestive Care Inc, Genentech, Gilead Sciences, Insmed, Novartis, Savara, and Vertex. D.vD. has served in the past year as an advisor/consultant for Affinium Pharmaceuticals, Aptalis Pharma, Aradigm, Baxter Healthcare, the US CF Foundation, CURx Pharma, Forest Pharmaceuticals, Genentech, Gilead Sciences, ICON Clinical Sciences, Kalobios, Vertex, and MedImmune. D.P. is employed by ICON Clinical Research, which provides clinical research services to pharmaceutical, biotechnology, and device companies.


© 2014  Elsevier Inc. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 165 - N° 6

P. 1091 - décembre 2014 Retour au numéro
Article précédent Article précédent
  • Enteral Nutrition in the Management of Pediatric Intestinal Failure
  • Kerri B. Gosselin, Christopher Duggan
| Article suivant Article suivant
  • 50 Years Ago in The Journal of Pediatrics : The Effect of Alkali and Glucose Infusion on Permanent Brain Damage in Rhesus Monkeys Asphyxiated at Birth
  • Catherine S. Forster

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.